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1. INTRODUCTION 
Connective tissue disease (CTD), also named collagen vascular disease, are various 
systemic autoimmune diseases characterized by autoimmune phenomena and 
immune-mediated organ dysfunction (Olson et al., 2012). The primary target of pathology 
is the connective tissue of the body. The connective tissue functions as the structural 
portion of our body and is composed of two major structural proteins, collagen and elastin. 
The abnormal immune system directed against one's own body tissues (autoimmunity) 
causes chronic inflammatory injury to tissues which may even prove lethal (Janeway et al., 
2001). According to the heterogeneous clinical features, CTDs are classified into systemic 
lupus erythematosus (SLE), systemic sclerosis (scleroderma, SSc), primary Sjögren’s 
syndrome (SS), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), 
antisynthetase syndrome (ASS), mixed CTD (MCTD) and undifferentiated CTD (UCTD) 
(Fischer and du Bois, 2012). 
The lung is a vulnerable target of autoimmune mediated injury in patients with CTD 
because of its abundant vasculature and large content of connective tissue. Pulmonary 
involvement may be the first manifestation of the disease (Yazisiz et al., 2010). Every 
component of the respiratory tract can be affected, including the interstitium, the large and 
small airways, the pleura and the pulmonary vasculature (de Lauretis et al., 2011). 
Interstitial lung diseases (ILD) is a common respiratory involvement which has been 
proved to occur in all kinds of CTDs (overall incidence of 15%), especially in patients with 
SSc and RA (de Lauretis et al., 2011; Fischer and du Bois, 2012). High-resolution 
computed tomography (HRCT) demonstrated that about two-thirds of the SSc patients 
have interstitial lung involvement, and postmortem examination validated that nearly all 
cases had developed pulmonary fibrosis (Launay et al., 2006). In patients with RA, up to 30% 
were found to have ILD, even though it was clinically apparent in only 5 to 10% of patients 
(Froidevaux-Janin et al., 2011). ILD is seen less frequently in SLE, but still 4% of patients 
with SLE have been found to develop pulmonary fibrosis (Park et al., 2007). 
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ILDs, also called diffuse parenchymal lung diseases (DPLDs), are characterized by 
inflammation and/or fibrosis of the lung parenchyma (Travis et al., 2013). They are a 
heterogeneous group of disorders typically presenting with progressive dyspnea and 
restrictive ventilatory impairment of pulmonary function. The diagnosis is mainly based on 
clinical and HRCT findings, sometimes histopathological confirmation is necessary   
(Travis et al., 2013). ILDs are divided into two main groups according to etiology: the 
idiopathic interstitial pneumonia (IIP), whose underlying cause is unknown, including 
idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (iNSIP), 
and cryptogenic organizing pneumonia (COP). Other groups of ILDs are those of known 
origin like hypersensitivity pneumonitis (HP) or the granulomatous disorders such as 
sarcoidosis (ATS/ERS, 2002). 
IPF is a chronic, progressive and ultimately fatal disease of unknown aetiology (Costabel, 
2003; Raghu et al., 2011). It is the most common form of IIPs, the annual incidence is 
estimated at 3-9 cases per 100,000 for Europe and North America (Hutchinson et al., 
2015). IPF is mainly diagnosed in older adults and has a predominance in men and 
ex/current smokers (Raghu et al., 2011). The median survival time of IPF is 3 to 5 years 
following diagnosis. Its prognosis is even worse than for many cancers (Fernandez et al., 
2010; Ley et al., 2011; Raghu et al., 2011). Although the pathogenetic mechanisms of IPF 
remain to be determined, recurrent injury to the alveolar epithelium is believed to be the 
early pathogenic event in IPF (Katzenstein and Myers, 1998; Wynes et al., 2001; Phan, 
2008), and then the migration and proliferation of fibroblasts and extracellular matrix 
remodeling result in irreversible distortion of the lung’s architecture which is characterized 
by the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) 
(Selman et al., 2001; Harari and Caminati, 2010). 
NSIP is the second most frequent cause of IIP, about 14%-36% of patients with IIP receive 
a diagnosis of NSIP (Kligerman et al., 2009). When no underlying causes and associations 
have been identified the diagnosis of idiopathic NSIP (iNSIP) is made, but more commonly 
NSIP occurs in a wide variety of clinical contexts, including toxic effects of drugs, 
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hypersensitivity pneumonitis, occupational exposure, and CTD (Travis et al., 2008). The 
histology of NSIP may range from a predominantly inflammatory process (i.e. cellular NSIP) 
to predominant fibrosis (i.e. fibrotic NSIP), but cellular NSIP is much less common than 
fibrotic NSIP (Katzenstein and Fiorelli, 1994). In contrast to IPF, NSIP shows a relatively 
homogeneous involvement of the alveolar walls by inflammation and fibrosis; bilateral 
ground-glass opacity is the most common HRCT pattern (Silva et al., 2008; Travis et al., 
2013). NSIP has a considerably better prognosis with a 5-year survival of 80% compared 
to approximately 30% for IPF (Tafti et al., 2008; Kligerman et al., 2009). 
In CTDs the manifestations of ILDs vary widely, with certain patterns more frequent than 
others in individual CTDs (Table 1). The most prevalent histologic pattern complicating 
SSc is fibrotic NSIP followed by the UIP pattern (Kim et al., 2002; Fischer et al., 2008). 
NSIP is also seen frequently in PM/DM and MCTD, whereas RA is more frequently 
associated with a UIP pattern (Kocheril et al., 2005). The ILD presenting in CTDs is a 
significant cause of mortality, especially in patients with SSc where ILD has become the 
leading cause of death. In RA, ILD contributes to increased mortality in up to 10% of 
patients (Olson et al., 2012). 
 Table 1. Types of ILD encountered in CTDs (Tzelepis et al., 2008) 
Diagnosis SSc PM/DM SS RA SLE MCTD 
Usual interstitial pneumonia ++ ++ + ++ + + 
Nonspecific interstitial pneumonia ++++ ++++ + + ++ ++ 
Cryptogenic organising pneumonia + ++ + + + − 
Diffuse alveolar damage + ++ + + ++ − 
Lymphocytic interstitial pneumonia − − +++ − − − 
+: lowest frequency; ++++: highest frequency; −: rare pulmonary involvement.  
When ILDs occur in association with CTDs, they may present before, during or after the full 
manifestation of the defined criteria for a given CTD (Tzelepis et al., 2008). If presenting 
before, ILDs may be the only manifestation and precede the extrapulmonary CTD 
manifestation by several months, sometimes by more than 5 years (Homma et al., 1995). 
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The radiological and histological characteristics of CTD-ILDs are similar to their idiopathic 
counterparts (Hwang et al., 2009). There are, however, significant differences in survival 
and management between patients with CTD-ILD and those with IIP. Although CTD 
patients presenting with ILDs have an increased mortality compared to those without ILD, 
they have a better survival than patients with IIP. CTD patients with a chronic ILD usually 
experience a stable or slowly progressive course (Antoniou et al., 2009). CTD-ILD may be 
responsive to anti-inflammatory or immunosuppressive treatment which can improve lung 
function and health-related quality of life (Tashkin et al., 2006), whereas anti-inflammatory 
therapy has been shown to be ineffective for IPF, and is not recommended by the 
ATS/ERS international guideline (Raghu et al,. 2011). By contrast with IIPs, the patients 
with CTD-ILD need more surveillance and guiding management decisions for specific 
extrathoracic disease manifestations (Fischer et al., 2012). Along these lines it is crucially 
important to distinguish CTD-ILD from IIP. If patients with occult CTD-ILD and with no 
consistent evidence of autoimmune disease are misdiagnosed as IIP, they may be 
deprived of the appropriate therapeutic regimen or subjected to unwarranted therapies. 
Since it is sometimes impossible for the physician to determine the diagnosis only based 
on the lung features, autoimmune screening should be done in all patients with apparent 
idiopathic ILDs. According to the recent guidelines for diagnosis and management of IPF, 
serologic tests for CTD should be performed in the majority of IPF patients (Raghu 
et al., 2011). The serologic evaluation should include rheumatoid factor, anti-cyclic 
citrullinated peptide, and antinuclear antibody (ANA) titer and pattern. 
The presence of autoantibodies directed against cytoplasmic and nuclear autoantigens of 
protein or nucleic acid nature is considered as a serological hallmark of systemic 
autoimmune rheumatic disease. In 1958, Friou first described an indirect 
immunofluorescence (IIF) assay for ANA detection (Friou et al., 1958). Initially the ANA IIF 
test relied on rodent tissue substrates but contemporary the human larynx 
epithelioma-HEp-2 cells (human epithelioma type 2-CCl 23 ATCC clone) are used as ideal 
substrate in this assay (Plebani et al., 2009). HEp-2 cells have a large nucleus and consist 
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of hundreds of potential autoantigens which significantly improves the sensitivity of ANA 
detection. The IIF assay on HEp-2 cells was recommended as the “gold standard” assay to 
screen for ANAs in sera by a task force of the American College of Rheumatology (ACR) 
(Meroni and Schur, 2010). 
The IIF used for ANA determination includes more than 25 patterns, many of them are 
directed against nuclear components and are usually specific for a particular CTD, greatly 
aiding the diagnostic process (de Lauretis et al., 2011). There are three major ANA patterns: 
the homogeneous pattern (associated with ANAs against double-stranded DNA (dsDNA) 
[SLE] and histones), the speckled/peripheral pattern (less specific) and the nucleolar 
pattern (most often associated with limited scleroderma). 
Specific serum ANA subsets have been shown to be related with pulmonary manifestations 
in CTD patients. For instance, in SSc, antibodies reactive with topoisomerase I (anti-ATA 
antibodies; also termed Scl-70) are associated with a greater risk of ILD, while 
anticentromere antibodies (ACAs) are rarely seen in SSc-ILD (Fischer and du Bois, 2012). 
Among patients with SS, pulmonary complications arise particularly in the anti-La/Ro 
antibody positivity individuals (Davidson et al., 2000; Yazisiz et al., 2010). Ferreira et al 
reported that anti-Ro52 antibodies are very sensitive (100%) for ILD diagnosis in MCTD, 
UCTD and SS (Ferreira et al., 2012). 
ANAs are not specific for CTDs, since approximately 20% of apparently healthy individuals 
have a positive IIF ANA test (Watanabe et al., 2004). The limited specificity has been one 
of the most important drawbacks of the HEp-2 IIF assay as a screening test for CTD (Mariz 
et al., 2011). The main target of the positive ANA pattern seen in healthy individuals is the 
dense fine speckled 70 antigen (DFS70) (Watanabe et al., 2004; Mariz et al., 2011). The 
recognition of this dense fine speckled ANA pattern is important to discriminate healthy 
individuals from CTD patients.  
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(a) DFS pattern 
 
(b) Patterns to be differentiated from DFS pattern 
 
Speckled pattern              Homogenous + nucleolar pattern            Homogenous pattern 
Figure 1. Characteristic features of various ANA patterns. DFS pattern is characterized by dense 
fine speckles in the nucleus of interphase cells and by strong chromatin staining in the metaphase of 
mitotic cells (a), the DFS pattern has to be differentiated from speckled patterns and homogeneous 
patterns (b) (Mahler et al., 2011; Mahler and Fritzler, 2012). 
The DFS pattern on HEp-2 cells is characterized by dense fine speckles in the nucleus of 
interphase cells and by strong chromatin staining in the metaphase of mitotic cells. It is a 
common ANA-IIF pattern, in recent studies 0.8% to 37% of samples showed the typical 
DFS-IIF pattern in consecutive samples tested for ANA (Ochs et al., 2016). Identification of 
the DFS pattern is not always easy, the discrimination between DFS and a homogeneous 
pattern can be a challenge for routine diagnostic laboratories (Figure 1). Recently, Mahler 
and colleagues developed an immunoadsorption IIF assay, a method that dilutes the 
patient serum samples in a buffer containing recombinant DFS70 antigen before the 
routine process of IIF, in this way anti-DFS70 antibodies can be prevented from binding to 
their target on HEp-2 substrate and producing the DFS pattern. They believe this novel 
assay can significantly improve the performance characteristics of ANA by IIF (Mahler, et 
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al., 2011). Besides IIF, the presence of anti-DFS70 antibodies can be analyzed by other 
techniques including enzyme-linked immunosorbent assay (ELISA), chemiluminescent 
assay, addressable laser bead assay, and immunoblot. Anti-DFS70 antibodies are 
predominantly IgG (Ochs et al., 2000; Mahler et al., 2012). 
The anti-DFS70 target autoantigen DFS70 was initially identified in the 1990s during a 
survey of ANAs in patients with interstitial cystitis and was termed for a 70-kDa protein 
recognized by immunoblotting (Ochs et al., 1994). Later the complete DFS70 DNA was 
sequenced and shown to be identical to the lens epithelium-derived growth factor (LEDGF) 
and DNA binding transcription coactivator p75 (Ge et al., 1998; Singh et al., 1999). DFS70 
consists of 15 exons and 14 introns (Singh et al., 1999). Its N-terminal region contains a 
proline-tryptophan-tryptophan-proline domain, charged regions, AT-hook motifs and a 
nuclear localization signal, all these sequences act as chromatin-binding elements 
cooperating to bind DFS70 to active transcription sites in the chromatin (Ochs et al., 2016). 
The C-terminal region contains the autoepitope (residues 347-435) recognized by the 
autoantibodies. This autoepitope is absent in the short splice variants of DFS70 (i.e. 
LEDGF/p52) which can explain why anti-DFS70 antibodies consistently recognize a single 
band of 70-75 kD and not the LEDGF/p52 in immunoblots of cell lysates (Ogawa et al., 
2004).  
Although originally presumed to be a lens epithelial cell growth factor, compelling evidence 
indicates that the main function of DFS70 is to promote cell survival against cellular 
oxidative stress which can be induced by alcohol, UVB irradiation, serum starvation, 
certain viruses, cytotoxic drugs and other environmental stressors (Basu et al., 2012; Leitz 
et al., 2014). Both the N- and C-terminal regions contribute to its stress survival functions 
(Ochs et al., 2016). DFS70 transcripts are expressed in various human tissues and cells, 
including lens epithelial cells, keratinocytes, fibroblasts, cancer cells and most laboratory 
transformed cell lines (Singh et al., 2000; Huang et al., 2007). The transcriptional and 
function of DFS70 are regulated by many factors. Increased cellular expression of 
transcription factor Sp1 can lead to upregulation of DFS70 via a TATA-less promoter 
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activation (Desfarges et al., 2011). Transforming growth factor beta 1 (TGF-β1) and 
micro-RNAs (miRNAs) can also influence the expression of DFS70 (Sharma et al., 2003; 
Swaminathan et al., 2012). During apoptosis induced by caspase-3, DFS70 is cleaved to 
several fragments; this apoptotic cleavage impairs DFS70’s stress survival activity (Wu et 
al., 2002). Taken together, DFS70 is a key protein in maintaining the delicate balance 
between the crossroads of cell death and survival in response to stress through 
transcriptional activation of antioxidant and other protective genes (Ochs et al., 2016). 
In inflammatory conditions, there is a regulatory crosstalk between DFS70 and the 
inflammatory pathways. In HaCaT skin cells, overexpression of DFS70 has been shown to 
induce the IL-6/STAT3 signaling pathway (Takeichi et al., 2010). DFS70 can also stimulate 
the release of tumor necrosis factor and IL-8 from keratinocytes (Takeichi et al., 2011). The 
link between DFS70 and the inflammatory pathway may contribute to inflammatory 
processes. Along these lines, anti-DFS70 antibodies have been detected in patients with a 
variety of chronic inflammatory conditions, in cancer patients, and also in apparently 
healthy individuals (Watanabe et al., 2004; Daniels et al., 2005; Meroni and Schur, 2010). 
The highest prevalence of anti-DFS70 antibodies has been reported in patients with 
Vogt-Harada syndrome (66.7%) (Yamada et al., 2001) and atopic dermatitis (30%) (Ochs 
et al., 2000; Ayaki et al., 2002). In contrast, the prevalence of anti-DFS70 antibodies in 
autoimmune diseases such as CTD is significantly lower (~2-3%) (Ganapathy and Casiano, 
2004; Mahler et al., 2011). Anti-DFS70 autoantibodies could play a pathogenic role and 
might function in the removal of DFS70 and its cleavage fragments from cellular debris to 
prevent the release of intracellular self-antigens and danger signals (Wu et al., 2002). 
The higher prevalence of anti-DFS70 antibodies in healthy subjects than in autoimmune 
diseases supports the hypothesis that these autoantibodies can serve as protective or 
natural autoantibodies (Miyara et al., 2013). On the other hand, the presence of 
anti-DFS70 antibodies in apparently healthy individuals may be indicative of an undetected 
chronic inflammatory response. 
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The low frequency of anti-DFS70 autoantibodies in systemic autoimmune diseases has 
been confirmed by several comprehensive studies. Dellavance et al. evaluated over 
13,000 ANA positive samples of a general clinical laboratory by IIF and immunoblot and 
found that anti-DFS70 autoantibodies were seen in 37% of samples and more commonly 
associated with nonautoimmune conditions than with systemic autoimmune disease 
(Dellavance et al., 2005). Another study examined 500 systemic autoimmune rheumatic 
disease sera for the presence of anti-DFS70 antibodies and found that only 22 (4.4%) were 
positive. The majority, 18/22 (86%), of these anti-DFS70 antibody positive patients were 
also positive for other autoantibodies such as anti-dsDNA, anti-SS-A, or anti-U1-RNP 
(Muro et al., 2008). Interestingly, in regard to the long term outcome, after an average 
follow-up of 4 years, none of the healthy individuals with isolated anti-DFS70 antibody 
reactivity later developed a systemic autoimmune disease (Mariz et al., 2011). Taken 
together these findings indicate that anti-DFS70 antibodies are rarely observed in systemic 
autoimmune diseases, and when they are, they are usually accompanied by additional 
autoantibodies. Individuals producing only anti-DFS70 antibodies, and no other 
autoantibody, have a low likelihood to develop a systemic autoimmune disease. 
Anti-DFS70 antibodies have been investigated in only a few lung disorders. In a study of 
patients with atopic dermatitis, 16% of the patients with asthma were DFS70 positive 
compared with 30% of atopic dermatitis and 0% of healthy subjects (Ochs et al., 2000). 
Yamada et al. found that in patients with panuveitis, including also sarcoidosis patients, 
anti-DFS70 positivity was seen in 67% of patients versus 22% of healthy controls. 
Investigations on anti-DFS70 antibodies in ILD patients are lacking in the literature.  
Since NSIP and IPF are characterized by inflammation and fibrosis, and in consideration of 
the transcript expression of DFS70 in fibroblasts and the essential function of DFS70 in 
inflammatory conditions, we hypothesized that DFS70 is associated with the 
pathophysiology of these two ILDs, and anti-DFS70 antibodies might be abnormally 
expressed compared to healthy individuals. Furthermore, by comparing the expression of 
anti-DFS70 antibodies between ILD patients with and without CTD the present study was 
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conducted to investigate the potential value of anti-DFS70 antibody as a biomarker to 
exclude the development of CTD in ILDs. 
2. AIM OF THE STUDY 
The aim of the current study was to investigate the frequency of serum anti-DFS70 
antibodies and a possible correlation with ANA status in patients with IPF and NSIP. 
Additionally, we investigated the potential role of anti-DFS70 antibody to distinguish 
between CTD-ILD and IIP and to predict CTD development in patients diagnosed initially 
as IIP. Finally, we explored the potential correlations between anti-DFS70 antibodies and 
clinical parameters of pulmonary involvements.  
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3. METHODS 
3.1. Study population 
260 patients with ILDs were investigated, including 100 patients with NSIP and 160 
patients with IPF. These patients were admitted to the Ruhrlandklinik from April 2007 to 
August 2013. Two groups of controls were included: the healthy control (HC) group was 
composed of 49 blood donors; 35 SSc-ILD patients (13 from the Ruhrlandklinik, 22 from 
the Department of Internal Medicine, University of Verona, Italy) served as negative 
controls for anti-DFS70 antibodies (Karsten et al., 2015). 
Written informed consent was obtained according to institutional guidelines. The study was 
approved by the local IRB. Demographic and laboratory characteristics of the enrolled 
subjects are shown in Table 2.  
The IPF and NSIP patients were diagnosed based on clinical, radiographic, and 
histopathologic findings according to ATS/ERS criteria 2011 and 2013 respectively (Raghu 
et al., 2011; Travis et al., 2013). The SSc patients were diagnosed based on current criteria 
(van den Hoogen et al., 2013). 
During follow-up of the IPF and NSIP patients, the diagnosis of CTD was made by referring 
rheumatologists according to current criteria for the respective disease (Tan et al., 1982; 
Aletaha et al., 2010; Shiboski et al., 2012; van den Hoogen et al., 2013). All patients had a 
follow-up time of at least 2 years. 
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Table 2. Demographics and patents’ characteristics of the studied groups.  
Variables 
NSIP IPF SSc-ILD HC 
n=100 n=160 n=35 n=49 
Demographics     
Age, yrs 65±1*##§§§ 68±0.7###§§§ 57±2§§§ 34±2 
Gender 
male/female (n) 
47/53***#§§ 128/32### 9/26§§§ 36/13 
Smoking status‡ 
current/ex/non (n) 
2/39/29**##§§§ 5/100/30###§§§ 1/7/23§ 7/4/22 
BMI 28±0.4 28±0.5 27±1 - 
 Pulmonary function     
FVC, % pred. 70±2 70±1 78±5 - 
FEV1, % pred. 69±2 72±1 71±5 - 
DLco, % pred. 48±4 42±1## 55±4 - 
TLC, % pred. 68±2## 67±1## 78±4 - 
Blood gas analysis     
PaO2, mmHg 74±1 72±1 75±3 - 
PaCO2, mmHg 37±0.4 38±0.3 37±1 - 
AaDO2, mmHg 29±1 30±1 27±3 - 
SaO2, % 95±0.3 95±0.2 96±0.6 - 
Unless otherwise indicated, values are expressed as mean ± standard error of mean (SEM). 
Independent-t test or Chi-square test was used to calculate p value. 
*: p<0.05, **: p<0.01, ***: p<0.001 vs. IPF. 
#: p<0.05, ##: p<0.01, ###: p<0.001 vs. SSc-ILD. 
§: p<0.05, §§: p<0.01, §§§: p<0.001 vs. HC. 
‡: Smoking status was not available in all patients. 
3.2. Pulmonary function tests and blood gas analysis 
Pulmonary function tests and blood gas analysis measurements included forced vital 
capacity (FVC), forced expiratory volume in one second (FEV1), total lung capacity (TLC), 
diffusing capacity of the lung for carbon monoxide (DLco), partial pressure of oxygen in 
arterial blood (PaO2), arterial carbon dioxide tension (PaCO2), alveolar-arterial oxygen 
gradient (AaDO2) and arterial oxygen saturation (SaO2). 
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3.3. Indirect immunofluorescence assay for antinuclear antibody detection 
Serum samples were obtained at the initial presentation, and then were stored at -80°C 
until analyzed. Lactate dehydrogenase (LDH) in serum was routinely measured in the 
serological laboratory of our institution. 
The ANA-IIF assay was performed at the central laboratory of the University Hospital 
Essen according to the following protocol: The serum samples were diluted in 0.15M NaCl 
and 10 mM phosphate buffered saline (PBS), pH 7.4, and incubated with HEp-2 cells in 
two different dilutions, 1:80 and 1:320 (Euroimmun AG, BIOCHIPS 
TITERPLANE®-technique, EUROPLUS®, ANA-global test, FA1510-2010-1, Lübeck, 
Germany) at room temperature for 30 minutes. After washing twice with PBS-Tween for 10 
minutes, the slides were incubated with goat anti-human immunoglobulin fluorescein 
isothiocyanate in a dark chamber at room temperature for another 30 minutes. After 
washing twice as before, the slides were embedded with buffered glycerol and coverslips 
(Euroimmun AG, ZF1200-0120, Lübeck, Germany). Analysis was performed by expert 
observers using a fluorescence microscope at 488nm (EUROSTAR, Euroimmun, Lübeck, 
Germany, magnification of 400x). Internal positive and negative controls (provided by the 
manufacturer, Euroimmun AG) were used. ANA titers were determined by testing 
successive 2-fold dilutions of the serum and were considered as elevated when higher 
than 1:80. 
3.4. Enzyme-linked immunosorbent assay 
The concentrations of serum anti-DFS70 antibodies at baseline were measured using a 
commercially available ELISA kit (Medical and Biological Laboratories Co., Ltd., Fujioka 
City, Japan). The assay is currently intended for research use only. The ELISA was 
performed according to the manufacturer’s instructions. 
Each serum was diluted 1:101 by adding 10μl serum to 1ml Assay Diluent. 100μl Assay 
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Diluent (for blank), 100μl Calibrator and 100μl of each diluted serum sample were added to 
the microwell coated with the antigen DFS70. The plate was incubated at room 
temperature (20-30℃) for 60 minutes and then washed 4 times with solution to remove any 
unbound material. After adding 100μl working conjugate solution to each well, the plate 
was incubated at room temperature for another 60 minutes. After washing 4 times to 
remove any unbound conjugate, 100μl of substrate was added to each well. The plate was 
incubated for 60 minutes at room temperature and then the reaction was stopped by 
adding 100μl stop solution to each well. The optical density value of the plate was read by 
a spectro-photometer immediately, setting the test wavelength at 450nm and the reference 
at 620nm. Finally, the concentration of anti-DFS70 antibodies in the samples was 
calculated through a formula provided by the instructions.  
The cut-off for positivity was set at 400 U/ml in this study, which was twice the standard 
deviation of the average of the negative control group (36 SSc-ILD patients sera). 
3.5. Statistical analysis  
SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Continuous 
variables were evaluated for a normal distribution with the Kolmogorov-Smirnov test. 
Normally distributed parametric data were presented as mean ± SEM; nonnormally 
distributed data were presented as median (interquartile, IQR). Categorical variables, such 
as sex, age, prevalence of anti-DFS70 antibodies, were presented as either a percentage 
of the total or numerically, as appropriate. Comparison between two groups was done with 
Student’s t-test or Wilcoxon’s rank test for continuous variables, Chi-squared or Fischer’s 
exact test for categorical variables. Multiple comparisons were performed by 
Kruskal-Wallis test and stepwise step-down multiple comparisons. Spearman’s or 
Pearson’s correlation coefficient was obtained for linear correlations. P values lower than 
0.05 were considered statistically significant.
  19 
4. RESULTS 
4.1. Expression of investigated serum biomarkers 
4.1.1 Prevalence of ANA positivity 
Within the control groups, 20 of 35 (83%) SSc-ILD patients were ANA positive and all 49 
healthy controls were ANA negative. The prevalence of ANA positivity in both the NSIP and 
IPF groups was significantly lower than in SSc-ILD and significantly higher than in healthy 
controls (p<0.001, for all comparisons). Within the ILD groups, ANA was positive in 47 of 
100 (47%) NSIP patients and 51 of 160 (32%) IPF patients. The ANA positive percentage 
of NSIP patients was significantly higher than that of IPF patients (p<0.05) (Table 3). 
Table 3. The prevalence of investigated serum biomarkers in studied groups. 
Biomarkers 
NSIP IPF SSc-ILD HC 
n=100 n=160 n=35 n=49 
ANA (+), n (%) 47 (47)*###§§§ 51 (32)###§§§ 29 (83)§§§ 0 (0) 
Anti-DFS70 (+), n (%) 12 (12)§§ 31 (19)§ 2 (6)§§ 17 (35) 
Serum anti-DFS70 antibody 
levels‡, median (IQR) U/ml 
111 (134)§§§ 123 (265)§§§ 97 (140)§§§ 320 (253) 
Data expressed as number (n) or median (IQR). 
Chi-square or Mann-Whitney test was used to calculate p value. 
*: p<0.05 vs. IPF. 
###: p<0.001 vs. SSc-ILD. 
§: p<0.05, §§: p<0.01, §§§: p<0.001 vs. HC. 
‡: Anti-DFS70 antibody levels of SSc-ILD were normally distributed, but were also expressed as median (IQR) 
to compare with other groups. 
In the total individuals of ILD patients, ANA positivity had the same prevalence in men and 
in women (66, 38% vs. 32, 38%, p>0.05). We divided the age of ILD patients into 3 groups: 
≤60 yrs, 61～70 yrs and >70 yrs, and found that the frequency of ANA positivity was 
stable across these age groups (p>0.05) (Table 4). 
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Table 4. The prevalence of ANA in ILD patients categorized by gender and age groups. 
Variables ANA (+), n (%) ANA (-), n (%) p value 
Gender    
male  (n=175) 66 (38) 109 (62) n.s. 
Female  (n=85) 32 (38) 53 (62)  
Age    
≤60 yrs  (n=59) 26 (44) 33 (56) n.s. 
60~70 yrs  (n=92) 31 (34) 61 (66)  
>70 yrs  (n=109) 41 (38) 68 (62)  
Data expressed as number (n) and percentage (%). 
Chi-square test was used to calculate p value. 
n.s.= not significant 
4.1.2 Prevalence of anti-DFS70 antibody positivity 
Within the control groups, anti-DFS70 antibodies were positive in 17 of 49 (35%) healthy 
controls and 2 of 35 (6%) SSc-ILD patients, the difference was significant (p<0.01). The 
prevalence of anti-DFS70 antibody positivity in both the NSIP and IPF groups was 
significantly lower than in HC (p<0.05, respectively), and tended to be higher than in 
SSc-ILD (p>0.05, respectively). Within the ILDs groups, anti-DFS70 antibodies were 
positive in 12% of NSIP patients and 19% of IPF patients, the difference was not significant 
(p>0.05) (Table 3). 
In the total individuals of ILD patients, the prevalence of anti-DFS70 antibodies was not 
different between men and women (17% vs. 15%, p>0.05) and also not different between 
various age groups (p>0.05) (Table 5). 
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Table 5. The prevalence of anti-DFS70 antibodies in ILD patients categorized by gender 
and age groups. 
Variables Anti-DFS70 (+), n (%) Anti-DFS70 (-), n (%) p value 
Gender    
Male  (n=175) 30 (17) 145 (83) n.s. 
Female  (n=85) 13 (15) 72 (85)  
Age    
≤60 yrs  (n=59) 10 (17) 49 (83) n.s. 
60~70 yrs  (n=92) 15 (16) 77 (84)  
>70 yrs  (n=109) 18 (17) 91 (83)  
Data expressed as number (n) and percentage (%). 
Chi-square test was used to calculate p value.   
n.s.= not significant 
4.1.3 Serum anti-DFS70 antibody levels 
Within the control groups, the serum anti-DFS70 antibody levels in SSc-ILD and in HC 
were 97 U/ml (IQR: 140 U/ml) and 320 U/ml (IQR: 253 U/ml), respectively, the difference 
was significant (p<0.05). Both the NSIP and IPF patients had significantly lower serum 
anti-DFS70 antibody levels than HC (p<0.001, respectively); the levels were similar to 
SSc-ILD (p>0.05, respectively) and not different between NSIP and IPF patients (Table 3 
and Figure 2). 
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Figure 2. Comparisons of serum anti-DFS70 antibodies levels between ILD patients and 
control groups. Dots represent single patients, the central line represents the median and 
the whiskers represent the interquartile range. Kruskal-Wallis and stepwise step-down 
multiple comparisons test were used to calculate p value. 
In the total population of ILD patients, the serum anti-DFS70 antibody levels in men tended 
to be higher than in women, but the difference was not significant (123 U/ml, IQR: 227 U/ml 
vs. 98 U/ml, IQR: 216 U/ml, p>0.05) (Figure 3a), and there was no difference according to 
smoking status (Figure 3b). 
No association between anti-DFS70 antibody levels and age was observed (Figure 3c). 
Also the levels of anti-DFS70 antibodies were stable across the age groups: 94 U/ml (IQR: 
222 U/ml) in ≤60 yrs; 130 U/ml (IQR: 183 U/ml) in 61～70 yrs; 114 U/ml (IQR: 249 U/ml) 
in >70 yrs; p>0.05 (Figure 3d). 
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Figure 3. Within all the ILD patients, comparison of serum anti-DFS70 antibody levels 
categorized by gender (a), smoking status (b) and age groups (d). Dots represent single 
patients, the central line represents the median and the whiskers represent the interquartile 
range. Mann-Whitney or Kruskal-Wallis test was used to calculate p value. Correlation 
between serum anti-DFS70 antibody levels and age (c). Spearman’s correlation test was 
used to calculate p value. 
4.2. Expression of investigated serum biomarkers according to development of CTD 
During 24 months of follow-up, 37 ILD patients (34 NSIP and 3 IPF) developed CTD: 22 RA 
(59%), 7 SSc (19%), 4 ASS (11%), 2 SS (5%), 1 MCTD (3%), 1 UCTD (3%). All the 3 
CTD-UIP patients developed RA. The patients’ demographics and characteristics 
according to CTD development are shown in Table 6. 
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Table 6. Demographics and characteristics of patients according to CTD development. 
Variables 
IIP CTD-ILD SSc-ILD HC 
n=223 n=37 n=35 n=49 
Demographics     
Age, yrs 67±1###§§§ 64±2#§§§ 57±2§§§ 34±2 
Gender, male/female (n) 160/63***### 15/22§§ 9/26§§§ 36/13 
Smoking habits‡, current/ex/non (n) 7/122/49###§§§ 0/17/10##§§§ 1/7/23§ 7/4/22 
BMI 28±0.4 27±0.6 27±1 - 
Pulmonary function     
FVC, %pred. 70±1 69±4 78±5 - 
FEV1, %pred. 72±1* 65±3 71±5 - 
DLco, %pred. 43±1## 53±9 55±4 - 
TLC, %pred. 67±1## 70±3 78±4 - 
Blood gas analysis     
PaO2, mmHg 73±1 74±2 75±3 - 
PaCO2, mmHg 38±0.2 37±0.7 37±1 - 
AaDO2, mmHg 30±1 30±2 27±3 - 
SaO2, % 95±0.2 95±0.6 96±0.6 - 
Biomarkers     
ANA (+), n (%) 73 (33)***###§§§ 25 (68)§§§ 29 (83)§§§ 0(0) 
Anti-DFS70 (+), n (%) 37 (17)§§ 6 (16)§ 2 (6)§§ 17 (35) 
Serum anti-DFS70 levels, median (IQR) 
U/ml  
119 (232)§§§ 104 (175)§§§ 97 (140)§§§ 320 (253) 
Unless otherwise indicated, values are expressed as mean ± SEM. 
Independent-t test, Mann-Whitney test or Chi-square test was used to calculate p value. 
*: p<0.05, ***: p<0.001 vs. CTD-ILD. 
#: p<0.05, ##: p<0.01, ###: p<0.001 vs. SSc-ILD. 
§: p<0.05, §§: p<0.01, §§§: p<0.001 vs. HC. 
‡: Smoking status and BALF were not available in all individuals. 
Among the 260 ILD patients, 98 (38%) were ANA positive at baseline. The frequency of 
CTD development was significantly higher in those ILD patients who were ANA (+) (25/98, 
26%) than ANA (-) (12/162, 7%), p<0.001. 24 of the 25 (96%) ANA (+) patients who 
developed CTD had NSIP, only one had UIP. Among the ANA (-) CTD-ILDs, 10/12 (83%) 
were RA compared to 12/25 (48%) of ANA (+) CTD-ILDs. 
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The prevalence of ANA positivity in the IIP group (33%) was significantly lower than in 
CTD-ILD (68%) and significantly higher than in healthy controls (0%, p<0.05 respectively) 
(Table 6). Within the NSIP group, ANA were positive in 35% iNSIP patients which was a 
significantly lower percentage than in CTD-NSIP (71%) and SSc-ILD (83%) patients 
(p<0.001, respectively). The ANA positive percentage in IPF-UIP (32%) was also 
significantly lower than in SSc-ILD (p<0.001), but similar to CTD-UIP (33%, p>0.05). There 
were no significant differences between iNSIP and IPF-UIP, or CTD-UIP (P>0.05, 
respectively) (Figure 4). Although the difference between CTD-UIP and SSc-ILD was 
significant, when considering the small number of CTD-UIP (n=3), the result is 
questionable.  
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Figure 4. Prevalence of ANA positivity according to CTD development. Data expressed as 
percentage (%). Chi-square test was used to calculate p value. 
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The prevalence of anti-DFS70 antibody positivity in the IIP group (17%) was significantly 
lower than in healthy controls (35%, p<0.05) and not significantly different from CTD-ILD 
(16%, p>0.05) (Table 6). Anti-DFS70 antibodies were positive in 11% iNSIP patients, 
significantly less than in HC (p<0.05) and not significantly different from CTD-NSIP (15%) 
and SSc-ILD (6%), p>0.05 respectively. The anti-DFS70 antibody positive percentage of 
IPF-UIP (19%) was also significantly lower than HC (p<0.05) and similar to CTD-UIP (33%, 
p>0.05) but higher than in SSc-ILD (p=0.06). The prevalence of anti-DFS70 antibody 
positivity in CTD-NSIP was significantly lower than in healthy controls (p<0.05) and was 
similar to SSc-ILD (p>0.05). No significant difference was seen between CTD-UIP and 
SSc-ILD/HC, as well as between iNSIP and IPF-UIP, CTD-NSIP and CTD-UIP (P>0.05 for 
all comparisons) (Figure 5). 
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Figure 5. Prevalence of anti-DFS70 antibody positivity according to CTD development. 
Data expressed as percentage (%). Chi-square test was used to calculate p value. 
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The serum anti-DFS70 antibody levels in the IIP group (119 U/ml, IQR: 232 U/ml) were 
significantly lower than in healthy controls (320 U/ml, IQR: 253 U/ml, p<0.001), but not 
significantly different from CTD-ILD (104 U/ml, IQR: 175 U/ml, p>0.05) (Table 6). 
Anti-DFS70 antibody levels in iNSIP patients (119 U/ml, IQR: 125 U/ml), in IPF-UIP (123 
U/ml, IQR: 263 U/ml) and in CTD-NSIP (101 U/ml, IQR: 140 U/ml) were all significantly 
lower than in healthy controls (p<0.05 for all comparisons), but were similar to SSc-ILD (97 
U/ml, IQR: 140 U/ml, p>0.05 for all comparisons). No significant difference was seen 
between CTD-UIP and SSc-ILD/HC, as well as between iNSIP and IPF-UIP, CTD-NSIP or 
CTD-UIP (P>0.05 for all comparisons) (Figure 6). 
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Figure 6. Comparison of serum anti-DFS70 antibody levels according to CTD 
development. Dots represent single patients, the central line represents the median and 
the whiskers represent the interquartile range. Kruskal-Wallis and stepwise step-down 
multiple comparisons test were used to calculate p value. 
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4.3. Relationship between ANA and anti-DFS70 antibodies 
Among the ANA positive ILD patients, 20% were anti-DFS70 antibody positive. This was 
not significantly different from the ANA negative individuals who were positive in 14% 
(Figure 7a). 
The serum anti-DFS70 antibody level in ANA positive ILD patients was 119 U/ml (IQR: 232 
U/ml), not significantly different from ANA negative patients (97 U/ml, IQR: 162 U/ml, 
p>0.05) (Figure 7b). 
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Figure 7. Relationship between ANA and anti-DFS70 antibodies in all ILD patients. 
Frequency of anti-DFS70 antibody positivity according to ANA status (a). Data expressed 
as percentage (%). Chi-square test was used to calculate p value. Serum anti-DFS70 
antibody levels according to ANA status (b). Dots represent single patients, the central line 
represents the median and the whiskers represent the interquartile range. Mann-Whitney 
test was used to calculate p value. 
At baseline, among the ANA positive ILD patients, the prevalence of anti-DFS70 antibody 
positivity in IPF (25%) was significantly higher than in SSc-ILD (3%, p<0.05) and was also 
higher, but not significantly, than in NSIP (15%, p>0.05). Among the ANA negative subjects, 
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HC had the highest percentage of anti-DFS70 antibody positivity (35%), significantly higher 
than NSIP or IPF patients (9% and 17%, p<0.05 respectively) (Figure. 8). 
ANA (+) ANA (-)
0
10
20
30
40
NSIP
IPF
SSc-ILD
HC
n=127  n=217
15%
3%
25%
9%
17% 17%
35%
p<0.01
p<0.05
p<0.01
A
n
ti
-D
F
S
7
0
 a
n
ti
b
o
d
y
 (
+
) 
(%
)
 
Figure 8. Frequency of anti-DFS70 antibody positivity according to ANA status at baseline. 
Data expressed as percentage (%). Chi-square test was used to calculate p value. 
After follow-up, among the ANA positive subjects, the prevalence of anti-DFS70 antibody 
positivity in IIP (22%) tended to be higher than in CTD-ILD (16%, p>0.05). Among the ANA 
negative subjects, the prevalence of anti-DFS70 antibody positivity was similar in IIP (14%) 
and in CTD-ILD (17%), p>0.05 (Figure. 9). 
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Figure 9. Frequency of anti-DFS70 antibody positivity according to ANA status at baseline 
after CTD development. Data expressed as percentage (%). Chi-square test or Fisher’s 
exact test was used to calculate p value. 
4.4. Frequency of CTD development according to ANA and anti-DFS70 antibody 
status 
The distribution of the various categories of ANA/DFS70 status in all ILD patients at 
baseline is shown in Figure 10. 
 
Figure 10. Frequency of ANA and anti-DFS70 antibody status at baseline in all ILD 
patients.  
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The patients with ANA (+)/DFS70 (-) status showed the highest frequency of CTD 
development (27%) which was significantly higher than in patients with ANA (-)/DFS70 (-) 
status (7%), p<0.05, and higher than in patients with ANA (-)/DFS70 (+) status (9%), 
p=0.07 (Table 7). 
Table 7. Association of ANA and anti-DFS70 antibody status at baseline with development 
of CTD. 
diagnosis 
ANA (+)/DFS70 (+) ANA (+)/DFS70 (-) ANA (-)/DFS70 (+) ANA (-)/DFS70 (-) 
n=20 n=78 n=23 n=139 
IIP, n (%) 16 (80) 57 (73)*** 21 (91) 129 (93) 
CTD-ILD, n (%) 4 (20) 21 (27)*** 2 (9) 10 (7) 
Chi-square test was used to calculate p value. 
***: p<0.001 vs. ANA (-)/DFS70 (-). 
4.5. Relationship of anti-DFS70 antibodies with clinical/laboratory parameters 
4.5.1 Clinical/laboratory parameters according to anti-DFS70 antibody status 
Among the ILD patients, the serum levels of LDH were significantly lower in patients with 
anti-DFS70 antibody (+) than in patients with anti-DFS70 antibody (-) (254±8 vs. 287±5, 
p<0.01). Also in IIP patients, the LDH levels were significantly lower in anti-DFS70 antibody 
(+) than in anti-DFS70 antibody (-) patients (253±9 vs. 288±6, p<0.01) (Table 8). There 
was no significant difference in pulmonary function and blood gas analysis parameters 
between patients with and without anti-DFS70 antibodies in any patient group (p>0.05 for 
all comparisons) (Table 8). 
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Table 8. Clinical parameters of patient groups according to anti-DFS70 antibody status. 
Variables 
anti-DFS70 status of 
all ILD 
 anti-DFS70 status of 
IIP 
 anti-DFS70 status of 
CTD-ILD 
(+) 
n=43 
 (-) 
n=217 
 (+) 
n=37 
(-) 
n=186 
 (+) 
n=6 
(-) 
n=31 
Pulmonary function         
FVC, %pred. 70±3 70±1  70±3 70±1  72±10 69±4 
FEV1, %pred. 72±3 71±1  72±3 72±1  70±10 64±3 
DLco, %pred. 45±2 44±2  46±3 42±1  37±3 57±11 
TLC, %pred. 68±2 67±1  68±2 66±1  71±5 69±4 
Blood gas analysis           
PaO2, mmHg 75±2 73±1  74±2 73±1  78±5 73±2 
PaCO2, mmHg 38±0.5 38±0.3  38±0.5 38±0.3  35±1 38±1 
AaDO2, mmHg 27±2 30±1  27±2 30±1  28±4 31±2 
SaO2, % 96±0.3 95±0.2  96±0.3 95±0.2  96±1 95±1 
Biomarker         
LDH, U/l 254±8** 287±5  253±9** 288±6  266±19 279±14 
Values are expressed as mean ± SEM. 
Independent-t test was used to calculate p value. 
*: p<0.05, **: p<0.01 vs. anti-DFS70 (-). 
In the NSIP group, no significant difference in serum LDH was seen between patients with 
and without anti-DFS70 antibodies (p>0.05), though there was a numerical trend towards 
lower levels in anti-DFS70 antibody (+) patients (Table 9). Except for significantly lower 
levels of PaCO2 (mmHg) in anti-DFS70 antibody (+) patients than in anti-DFS70 antibody (-) 
patients (35±0.8 vs. 38±0.4, p<0.05), there were no differences in clinical characteristics 
between the NSIP groups according to anti-DFS70 antibody status (Table 9). 
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Table 9. Clinical parameters of NSIP patients according to anti-DFS70 antibody status. 
Variables 
anti-DFS70 status of 
NSIP 
 anti-DFS70 status of 
iNSIP 
 anti-DFS70 status of 
CTD-NSIP 
 (+) 
n=12 
(-) 
n=88 
 
 (+) 
n=7 
(-) 
n=59 
  (+) 
n=5 
(-) 
n=29 
Pulmonary function         
FVC, %pred. 65±6 70±2  62±7 71±2  70±13 69±4 
FEV1, %pred. 64±6 69±2  61±7 72±3  68±12 64±3 
DLco, %pred. 37±3 49±4  39±5 45±2  34±3 57±12 
TLC, %pred. 66±4 68±2  62±4 67±2  72±6 69±4 
Blood gas analysis             
PaO2, mmHg 75±3 74±1  71±3 75±2  81±2 73±2 
PaCO2, mmHg 35±0.8* 38±0.4  35±1 37±1  35±1 38±1 
AaDO2, mmHg 31±2 29±1  35±3 28±2  26±4 31±2 
SaO2, % 96±0.5 95±0.4  95±0.6 96±0.6  97±0.4 95±0.8 
Biomarker         
LDH, U/l 261±12 288±9  263±17 290±12  258±21 285±14 
Values are expressed as mean ± SEM. 
Independent-t test was used to calculate p value. 
*: p<0.05 vs. anti-DFS70 (-). 
In IPF patients, the levels of LDH were significantly lower in anti-DFS70 antibody (+) than 
in anti-DFS70 antibody (-) patients (252±10 vs. 286±6, p<0.05) (Table 10). In regard to 
pulmonary function parameters, DLco (%pred.) was significantly higher in anti-DFS70 
antibody (+) than in anti-DFS70 antibody (-) IPF patients (48±3 vs. 41±1, p<0.05), and the 
AaDO2 gradient was significantly lower in anti-DFS70 antibody (+) than in anti-DFS70 
antibody (-) IPF patients (26±2 vs. 31±1, p<0.05) (Table 10).  
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Table 10. Clinical parameters of IPF patients according to anti-DFS70 antibody status. 
Variables 
anti-DFS70 (+) 
n=31 
anti-DFS70 (-) 
n=129 
Pulmonary function   
FVC, %pred. 72±3 70±2 
FEV1, %pred. 75±3 71±2 
DLco, %pred. 48±3* 41±1 
TLC, %pred. 69±2 66±1 
Blood gas analysis     
PaO2, mmHg 75±2 71±1 
PaCO2, mmHg 39±0.5 38±0.3 
AaDO2, mmHg 26±2* 31±1 
SaO2, % 96±0.4 95±0.3 
Biomarker   
LDH, U/l 252±10* 286±6 
Values are expressed as mean ± SEM. 
Independent-t test was used to calculate p value. 
*: p<0.05 vs. anti-DFS70 (-). 
4.5.2 Correlations between serum anti-DFS70 antibody levels and clinical/laboratory 
parameters 
In all ILD patients, anti-DFS70 antibody levels weakly inversely correlated with LDH 
(rp=-0.125, p<0.05), the same weak correlation was seen in IIP patients (rp=-0.153, p<0.05). 
There was no other association between the clinical parameters and anti-DFS70 antibody 
levels (Table 11). 
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Table 11. Linear correlation of anti-DFS70 antibodies levels and clinical characteristics 
according to diagnosis. The table shows the Spearman’s correlation coefficients (rp). 
Variables 
ILD 
n=260 
IIP 
n=223 
CTD-ILD 
n=37 
Pulmonary function    
FVC, %pred. -0.011 -0.059 0.201 
FEV1, %pred. 0.017 -0.037 0.245 
DLco, %pred. 0.031 0.066 -0.217 
TLC, %pred. 0.011 -0.010 0.135 
Blood gas analysis    
PaO2, mmHg 0.042 0.024 0.139 
PaCO2, mmHg 0.052 0.117 -0.307 
AaDO2, mmHg -0.079 -0.081 -0.073 
SaO2, % 0.057 0.057 0.001 
Biomarker    
LDH -0.125* -0.153* 0.062 
*: p<0.05 
In iNSIP patients, anti-DFS70 antibody levels inversely correlated with FVC (%pred.) 
(rp=-0.320, p<0.05), FEV1 (%pred.) (rp=-0.393, p<0.01), TLC (%pred.) (rp=-0.360, p<0.01), 
and positively with AaDO2 (mmHg) (rp=0.263, p<0.05) (Figure 11), indicating more marked 
impairment of lung function and gas exchange in patients with higher anti-DFS70 antibody 
levels. 
In IPF patients, anti-DFS70 antibody levels weakly inversely correlated with LDH 
(rp=-0.196, p<0.05) and AaDO2 (mmHg) (rp=-0.199, p<0.05) (Figure 12). 
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Figure 11. Correlation of serum anti-DFS70 antibody levels with FVC (%pred.) (a), FEV1 
(%pred.) (b), TLC (%pred.) (c), and AaDO2 (mmHg) (d) in iNSIP patients. Dots represent 
single patients. Spearman’s correlation test was used to calculate p value. 
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Figure 12. Correlation of serum anti-DFS70 antibody levels with LDH (a) and AaDO2 
(mmHg) (b) in IPF patients. Dots represent single patients. Spearman’s correlation test 
was used to calculate p value. 
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5. DISCUSSION 
In the current study, we found that serum anti-DFS70 antibodies are less prevalent in ILD 
and SSc-ILD patients than in healthy controls. There was no significant difference in 
anti-DFS70 antibody expression according to the ANA status of ILD patients. During 
follow-up, ANA (+) ILD patients with negative anti-DFS70 antibody developed CTD more 
frequently. In patients with iNSIP a weak relationship was seen between serum anti-DFS70 
antibody levels and more pronounced impairment of lung function. To the best of our 
knowledge, this is the first study that investigated the role of anti-DFS70 antibodies in ILD 
patients.  
In the 1960s, Turner-Warwick was the first to describe that ANA are positive in nearly 50% 
of ILD patients (Turner-Warwick and Doniach, 1965). Later studies confirmed this, e.g. the 
study of Mittoo et al. who found 54% of patients were positive for at least one autoantibody 
(Mittoo et al., 2009). In our study, positive ANAs were observed in 47% of NSIP and 32% of 
IPF patients. In our CTD-ILD patients, ANA positivity was seen in 68% which is relatively 
low for a CTD cohort. This may be due to the composition of our CTD-ILD population, with 
59% being RA patients. RA is not considered to be an ANA-associated disease. Despite 
the fact that the prevalence of ANAs has been reported to be higher in healthy women than 
in healthy men (Fernandez et al., 2003; Hayashi et al., 2008) and higher in elderly than in 
younger healthy individuals (Candorec et al., 1997; Hurme et al., 2007), in the ILD subjects 
of our study we did not see a difference in the frequency of ANA positivity between gender 
and age groups. 
To avoid the low specificity of ANA-IIF test as screening test for systemic autoimmune 
rheumatic disease, subsequent immunoassays for specified antibodies are usually done. 
But there is no consistency in the recommendations for the use of autoantibodies and 
diagnostic algorithms in different serological laboratories (Mahler and Fritzler, 2012). It has 
been recommend to include Ro/SSA, La/SSB, Jo-1, Scl-70, Th/To, RNA-Polymerase III, 
Sm, dsDNA (SLE) and CCP in the serological examination of ILD patients (Bahmer et al., 
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2016). Since by now more than 150 different autoantibodies have been discovered, in 
consideration of feasibility and economic costs, it is impossible to include all CTD 
associated ANAs into ANA screening ELISA tests. Therefore, it would be useful to have a 
biomarker which would exclude CTD in patients with ILD and positive ANA serology but 
without symptoms of CTD. Such a biomarker could result in considerable cost-savings by 
adding accuracy to the ANA screening test. As such, Anti-DFS70 antibody is one of the 
best candidates since it seems to be helpful in discriminating between subjects with and 
those without autoimmune disease among ANA positive patients. 
The prevalence of anti-DFS70 antibodies has been reported to vary but consistent findings 
are that they are present in healthy ANA (+) individuals even when ANA reach moderate or 
high titers, and that they are rarely found in patients with CTD (Dellavance et al., 2005; 
Pazini et al., 2010; Miyara et al., 2013). Fitch-Rogalsky et al. investigated 643 patients with 
a positive ANA and found that 15% were anti-DFS70 antibody positive and 91% of these 
did not have an autoimmune disease (Fitch-Rogalsky et al., 2014). In a study of routine 
ANA screening DFS and traditional fine speckled patterns were the major ANA-IIF patterns, 
and 61% of DFS positivity was seen in nonautoimmune conditions (Dellavance et al., 
2005). Our study confirms this for patients with ILDs. Among the ANA positive ILD patients 
in our study, 20% of anti-DFS70 antibody positive patients developed CTD, in contrast to 
27% of anti-DFS70 antibody negative. This suggests that, compared with other ANAs, 
anti-DFS70 positivity decreases the likelihood of a CTD-ILD. 
Anti-DFS70 antibodies are not completely absent in CTD, and the coexistence with other 
autoantibodies should be taken into account. In a group of SLE patients, approximately 6% 
had anti-DFS70 antibodies, and all the anti-DFS70 antibody positive patients had 
additional autoantibodies which were included in the classification criteria for SLE (Muro et 
al., 2008). Similar data were reported in another study where the prevalence of anti-DFS70 
antibodies in SLE was 2.6%, and only one of the 7 anti-DFS70 (+) patients did not show 
other autoantibody reactivity (Mahler et al., 2012). 
  40 
The sensitivity of the ANA-IIF is influenced by the chosen cut off value for ANA titers. In the 
current study we set the positive value at the dilution of 1:160 as recommended by the ANA 
Subcommittee of the International Union of Immunological Societies Standardization 
Committee (Tan et al., 1997). We noted that 23 of the 43 anti-DFS70 antibody positive 
patients identified by ELISA were ANA negative on HEp-2 slides. Some investigators 
attribute such inconsistent results between various assays to different HEp-2 substrate 
preparations, the type of DFS70 epitope exposed in various assays, and the interobserver 
variation in the interpretation of the ANA-IIF pattern (Mahler et al., 2008; Bizzaro et al., 
2011). Fortunately, since anti-DFS70 antibodies are not associated with CTD, the low 
sensitivity in the ANA-IIP test will not affect the final diagnosis, because in most 
laboratories the patients with ANA negativity are ruled out to have a CTD. There is growing 
consensus that it is inadequate to use the ANA-IIF test as the sole method for the detection 
of autoantibodies (Mahler and Fritzler, 2012; Miyara et al., 2013), and the confirmatory 
ELISA test should include anti-DFS70 autoantibody. In our study, patients with both ANA 
and anti-DFS70 antibody negativity had a low likelihood of only 7% for developing CTD, 
and those with ANA positivity and anti-DFS70 antibody negativity had an increased 
likelihood of 27% for developing CTD during follow-up.  
In some studies, investigators observed that anti-DFS70 autoantibodies were more 
prevalent or had higher titers in females than in males (Ochs et al., 2000; Watanabe et al., 
2004). Our study, in agreement with others, did not find any such difference in gender 
groups (Mahler et al., 2012). Differences of cohort collection and disease composition may 
explain the discrepancy. An age dependency was shown in a study of 918 healthy 
individuals, more than 90% of the DFS patterns were observed in people younger than 50 
years (Mariz et al., 2011). However this was not confirmed in another study (Mahler et al., 
2012). Also in our study, the status of anti-DFS70 antibodies was similar across 3 age 
strata and showed no correlation with age. Smoking history is a risk factor for the 
development of some ILDs, including RA associated ILD (Saag et al., 1996; Gochuico et 
al., 2008). In the current study we did not find an association between smoking 
history/habit and anti-DFS70 antibodies in any patient group. 
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The clinical and biological significance of anti-DFS70 autoantibody is still puzzling. 
Although the autoantibodies can be induced by aberrant tissue manifestations of DFS70 
(i.e. overexpression, extracellular release, cell death cleavage), there is no apparent 
relationship between the levels of these antigens and antibodies in some human diseases. 
Daniels et al. observed a strong expression of DFS70 in benign prostatic hyperplasia 
tissue but an absent expression of anti-DFS70 autoantibodies in the patients’ sera. They 
speculated that the discrepancy could be due to the relatively low rates of cell death and 
decreased DFS70 cleavage fragments in the benign prostatic hyperplasia tissue which 
would be insufficient to induce the antibodies (Daniels et al., 2005). In another study, 36 
children with chronic nonspecific complaints (CFS) had much higher titers and a higher 
prevalence of anti-DFS70 antibodies than autoimmune fatigue syndrome, Kawasaki 
disease, SS, atopic dermatitis and normal human sera. It seems that CFS patients have 
some anti-stress dysfunction, such as sensitivity against UV exposure, infection, physical 
exercise, and even emotional crisis (Kuwabara et al., 2009). It is possible that in diseases 
characterized by anti-DFS70 antibody reduction, the anti-DFS70 antibodies which 
accumulate under ’normal’ condition, are cleared or neutralized by the overexpressed 
DFS70 antigen. 
In the current study we found that in all groups of ILD patients the anti-DFS70 antibody 
negative patients showed higher levels of LDH levels which is a nonspecific marker of 
tissue injury widely used to monitor the course of acute lung injury, indicating that the 
higher degree of tissue injury is possibly associated with a reduction of anti-DFS70 
antibodies. Interestingly, in iNSIP patients, anti-DFS70 antibody levels inversely correlated 
with lung function parameters, such as FVC (%pred.), FEV1 (%pred.) and TLC (%pred.), 
indicating that in this disease higher anti-DFS70 antibody levels are related with more 
marked functional impairment. Whether DFS70 has a pathogenic role or is merely a 
bystander in the pathogenesis of ILDs is unclear at present. 
In fibrotic ILDs TGF-β1 is a cytokine with many functions, including regulation of 
inflammation, cell growth and tissue fibrosis (Tahira et al., 2002). In lung fibrosis, TGF-β1 
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plays a significant role in fibrogenesis through the induction of myofibroblasts and the 
regulation of the synthesis and degradation of extracellular matrix (Sharma et al., 2003; 
Bonniaud et al., 2005). Based on HRCT scores, higher levels of TGF-β1 have been found 
to be associated with progressive lung disease in various kinds of ILD (Szlubowski et al., 
2010). In the context of DFS70, TGF-β1 has been shown to down regulate DFS70 
expression by diminishing its affinity for DNA binding in human lens epithelial cells (Sharma 
et al., 2003). In a Prdx6-/- knockout mouse cell line, increased TGF-β1 levels were 
observed combined with reduced DFS70, and in the lenses of diabetic and galactosemic 
cataractous rats, an inverse relationship between the expression of TGF-β1 and DFS70 
was seen (Fatma et al., 2005). Based on these observations, the overexpression of 
TGF-β1 in ILDs might inhibit the induction of DFS70 (Miki et al., 2000; Honda et al., 2010). 
MiRNAs are small RNA molecules and play important roles in many physiological 
processes such as cellular proliferation, tissue development, differentiation and repair (Lau 
et al., 2001). The miRNAs can also influence the expression of DFS70 at the 
transcriptional level, such as shown for miR-155 which reduced DFS70 levels 
(Swaminathan et al., 2012). The expression of miR-155 has been shown to highly correlate 
with profibrotic gene expression (Christmann et al., 2016). In the intratracheal bleomycin 
murine lung model, miR-155 was upregulated, and miR-155-deficient mice developed 
milder lung fibrosis (Christmann et al., 2016). in IPF, upregulation of miR-155 has been 
observed (Pandit et al., 2010). Taken together, DFS70 may be downregulated by increased 
miR-155 in patients with IPF. 
Our study has several limitations, First, the exact ANA-IIF pattern was not available in all 
individuals, and we cannot analyze which autoantibodies coexist with anti-DFS70 antibody 
in CTD-ILD patients. Second, the number of CTD-UIP patients was very small (n=3), 
because few IPF patients developed CTD. Third, measurement of DFS70 levels in 
BALF/tissue was not performed and should be done in further studies. Comparing lung 
tissue expression of DFS70 versus circulating levels of anti-DFS70 antibodies would be 
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important to explore the potential function of this antigen-antibody system in the 
pathogenesis of ILDs. 
In conclusion, the prevalence and serum levels of anti-DFS70 antibodies were highest in 
healthy subjects and decreased in patients with ILDs and SSc-ILD. Most of the ILD 
patients who developed CTD during follow-up were shown to be characterized by ANA 
positivity combined with anti-DFS70 antibody negativity. The potential function of DFS70 
and the anti-DFS70 antibody system in the pathogenesis of ILDs needs to be further 
investigated. 
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6. SUMMARY 
Anti-DFS70 antibodies, corresponding to the dense fine speckled ANA indirect 
immunofluorescence pattern in HEp-2 substrates, have been observed in chronic 
inflammatory conditions, cancer and in healthy individuals but only in a small percentage of 
patients with systemic autoimmune rheumatic diseases. The aim of this study was to 
investigate the role of anti-DFS70 antibodies as biomarker in ILD. We evaluated its value 
to distinguish connective tissue disease associated interstitial lung disease (CTD-ILD) from 
idiopathic interstitial pneumonia (IIP). In addition, we explored potential correlations 
between anti-DFS70 antibodies and clinical parameters. 
Methodologically, serum samples were collected from 49 healthy controls, 35 
scleroderma-ILD (SSc-ILD) patients as negative controls for anti-DFS70 antibody, and 260 
patients with ILDs. The ILD patients included 100 nonspecific interstitial pneumonia (NSIP) 
and 160 idiopathic pulmonary fibrosis (IPF) patients. The serum anti-DFS70 antibodies 
were assessed by enzyme-linked immunosorbent assay. 
The frequency and levels of serum anti-DFS70 antibodies were lower in ILD and SSc-ILD 
patients compared to healthy controls. Thirty-seven patients developed CTD during 24 
months of follow-up (3 initial IPF and 34 initial idiopathic NSIP patients), most of them 
combined with ANA positivity and anti-DFS70 antibody negativity. Anti-DFS70 antibodies 
were not significantly different between CTD-ILD and idiopathic ILD. Anti-DFS70 antibody 
concentrations were inversely correlated with pulmonary functions in iNSIP. 
In conclusion, the frequency and levels of serum anti-DFS70 antibodies are markedly 
decreased in patients with ILDs. Anti-DFS70 antibodies may play a role to predict CTD 
development in ILD patients. 
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8. ABBREVIATIONS 
AaDO2 alveolar-arterial oxygen gradient 
ACA anticentromere antibody 
ACR American College of Rheumatology 
ANA antinuclear antibody 
ANA-IIF Indirect immunofluorescence assay for antinuclear antibody detection  
ASS antisynthetase syndrome 
CFS chronic fatigue syndrome 
COP cryptogenic organizing pneumonia 
CTD connective tissue disease 
CTD-ILD connective tissue disease associated interstitial lung disease 
DFS70 dense fine speckled 70 antigen 
DLco diffusing capacity of the lung for carbon monoxide 
DPLD diffuse parenchymal lung disease 
dsDNA double-stranded DNA 
ELISA Enzyme-linked immunosorbent assay 
FEV1 forced expiratory volume in one second 
FVC forced vital capacity 
HC healthy control 
HEp-2 human epithelioma type 2-CCl 23 ATCC clone 
HP hypersensitivity pneumonitis 
HRCT high resolution computed tomography; 
IIF indirect immunofluorescence 
IIP idiopathic interstitial pneumonia 
IL interleukin 
ILD interstitial lung disease 
iNSIP idiopathic nonspecific interstitial pneumonia 
IPF idiopathic pulmonary fibrosis 
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IQR interquartile 
LDH Lactate dehydrogenase 
LEDGF lens epithelium-derived growth factor 
MCTD mixed connective tissue disease 
miRNA micro-RNA 
NSIP nonspecific interstitial pneumonia 
PaO2 arterial oxygen tension 
PBS phosphate buffered saline 
PaCO2 arterial carbon dioxide tension 
PM/DM polymyositis/dermatomyositis 
RA rheumatoid arthritis 
SaO2 arterial oxygen saturation 
SEM standard error of mean 
SLE systemic lupus erythematosus 
SS sjögren’s syndrome 
SSc systemic sclerosis 
TGF-β1 transforming growth factor beta 1 
TLC total lung capacity 
UCTD undifferentiated connective tissue disease 
UIP usual interstitial pneumonia 
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